Table 1.
Characteristics of included studies
| Author (trial) | Year | ESR1 mutations panel | No. of patients analyzed for ESR1 | No. of ESR1 mutations-positive patients | Subsequent treatment | Sample type | Detection methods | Sampling time | Outcome | NOS |
|---|---|---|---|---|---|---|---|---|---|---|
| Schiavon et al19 | 2016 | D538G Y537S L536R Y537N Y537C | 171 | 18 | AI-based therapy | ctDNA | ddPCR | Baseline | PFS | 9 |
| Clatot et al21 | 2016 | D538G Y537S Y537N Y537C | 144 | 44 | AI based, chemotherapy, others | cfDNA | ddPCR | Baseline | PFS, OS | 8 |
| Fribbens et al22 (SoFEA) | 2016 | D538G Y537S Y537N E380Q | 161 | 63 | Fulvestrant + anastrozole/placebo, exemestane | ctDNA | Multiple xddPCR | Baseline | PFS, OS | 9 |
| Fribbens et al22 (PALOMA3) | 2016 | D538G Y537S Y537N E380Q | 360 | 91 | Fulvestrant + palbociclib/placebo | ctDNA | Multiple xddPCR | Baseline | PFS | 9 |
| Spoerke et al23 (FERGI) | 2016 | D538G Y537S E380Q Y537N Y537C P535H L536H L536P L536Q L536R | 153 | 57 | Fulvestrant + pictilisib/placebo | ctDNA | BEAMing | Baseline | PFS | 9 |
| Chandarlapaty et al20 (BOLERO-2) | 2016 | D538G Y537S | 541 | 156 | Exemestane + placebo/everolimus | cfDNA | ddPCR | Baseline | PFS, OS | 9 |
Abbreviations: AI, aromatase inhibitor; ct, circulating tumor; cf, cell free; dd, droplet digital; NOS, Newcastle–Ottawa Scale; OS, overall survival; PCR, polymerase chain reaction; PFS, progression-free survival.